The Effect of Ketanserin on the Microcirculation in Sepsis
NCT ID: NCT01329887
Last Updated: 2014-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
10 participants
INTERVENTIONAL
2011-03-31
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Nitroglycerine on Microcirculatory Abnormalities During Sepsis
NCT00493415
The Application of SERS and Metabolomics in Sepsis
NCT02213237
Effects of Norepinephrine and Volume Expansion in Capillary Refill Time in Septic Shock
NCT04870892
The Effect of Increasing the Mean Arterial Pressure on the Microcirculation and the Prognosis of Patients With Septic Shock
NCT04136080
Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock
NCT00279214
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
administration of ketanserin
ketanserin
ketanserin administration is started and increase, guided by the effect on sublingual MFI, dosage is 0,03mg/kg/hr
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ketanserin
ketanserin administration is started and increase, guided by the effect on sublingual MFI, dosage is 0,03mg/kg/hr
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* pregnant
* participation other trials prolonged Qt interval
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Frisius Medisch Centrum
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
E.C. Boerma
Dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
E Boerma, MDPhD
Role: PRINCIPAL_INVESTIGATOR
Frisius Medisch Centrum
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Centre Leeuwarden
Leeuwarden, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TPO 736
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.